SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Total Equity
SCI Pharmtech Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Equity
NT$5.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Equity
NT$7.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Equity
NT$11B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Equity
NT$22.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Equity
NT$5.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Total Equity
NT$9.7B
|
CAGR 3-Years
147%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Total Equity?
Total Equity
5.4B
TWD
Based on the financial report for Sep 30, 2025, SCI Pharmtech Inc's Total Equity amounts to 5.4B TWD.
What is SCI Pharmtech Inc's Total Equity growth rate?
Total Equity CAGR 10Y
8%
Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for SCI Pharmtech Inc have been 15% over the past three years , 8% over the past five years , and 8% over the past ten years .
